MARKET

NWBO

NWBO

Northwest Bio
OTCMQB

Real-time Quotes | Nasdaq Last Sale

0.678
-0.018
-2.52%
Closed 15:59 05/20 EDT
OPEN
0.701
PREV CLOSE
0.695
HIGH
0.701
LOW
0.678
VOLUME
1.19M
TURNOVER
815.07K
52 WEEK HIGH
2.150
52 WEEK LOW
0.386
MARKET CAP
650.41M
P/E (TTM)
3.467
1D
5D
1M
3M
1Y
5Y
Northwest Bio plunges after late-stage data for lead candidate in brain cancer
The shares of Northwest Biotherapeutics (OTCQB:NWBO) reached a 52-week low on Tuesday after the clinical-stage immunotherapy company announced a presentation with Phase 3 data for its lead asset DCVax-L in
Seekingalpha · 05/10 16:52
Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that, as previously announced, a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic C...
PR Newswire · 05/10 14:19
Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Gliobl...
PR Newswire · 05/04 15:35
If You Invested $1000 In Northwest Biotherapeutics 5 Years Ago, Here's How Much You Would Have Today
Northwest Biotherapeutics (OTC:NWBO) has outperformed the market over the past 5 years by 42.99% on an annualized basis producing an average annual return of 54.57%. Currently, Northwest Biotherapeutics has a market capitalization of $1.42 billion.
Benzinga · 05/03 15:03
Northwest stock rises 9% as company begins cancer vaccine production at UK facility
Northwest Biotherapeutics (OTCQB:NWBO +7.6%) began production of its first dendritic cell cancer vaccine for a compassionate use patient at its production facility in Sawston, U.K. The company said the milestone follows
Seekingalpha · 02/17 14:49
Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced commencement of production of its first dendritic cell cancer vaccine for a compassionate u...
PR Newswire · 02/17 14:20
Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing At Sawston, UK Facility
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that approval has been received from the UK Medicines and Healthcare Products Regulatory Ag...
PR Newswire · 12/21/2021 14:24
Northwest Biotherapeutics secures $15M financing on stock purchase rights
Northwest Biotherapeutics (OTCQB:NWBO +12.3%) has closed on $15M financing, which brings the company's cash reserves above $20M. The financing is in the form of a 22-month loan which requires no
Seekingalpha · 11/29/2021 16:11
More
No Data
Learn about the latest financial forecast of NWBO. Analyze the recent business situations of Northwest Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.64%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/President/Chief Executive Officer/Chief Financial Officer/Chief Accounting Officer/Director
Linda Powers
Senior Vice President/General Counsel
Leslie Goldman
Chief Technology Officer
Marnix Bosch
Chief Scientific Officer/Director
Alton Boynton
Lead Director/Independent Director
Jerry Jasinowski
Independent Director
J. Cofer Black
Independent Director
Navid Malik
No Data
No Data
About NWBO
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company's lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company's platform technology, DCVax, uses activated dendritic cells to mobilize a patient's own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.

Webull offers kinds of Northwest Biotherapeutics, Inc stock information, including OTCMQB:NWBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NWBO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NWBO stock methods without spending real money on the virtual paper trading platform.